CD274 and esophageal squamous cell carcinoma: In advanced ESCC, PD-L1 is a predictive biomarker for pembrolizumab,[6] but the effectiveness of camrelizumab or tislelizumab was not associated with PD-L1 expression.[30,31] In the present study, the ORR was 88.9% (8/9) in PD-L1 CPS ≥ 10 patients, and 61.5% (8/13) in PD-L1 CPS < 10 patients.